Small Interfering Ribonucleic Acid (RNA) Market Expansion Is Reshaping Competitive Dynamics Across The Industry
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Small Interfering Ribonucleic Acid (RNA) Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for small interfering ribonucleic acid (RNA) has experienced exponential expansion in recent years. Projected to rise from $18.86 billion in 2025 to $22.69 billion in 2026, it is expected to achieve a compound annual growth rate (CAGR) of 20.3%. This historical growth has been driven by progress in molecular biology research, a growing incidence of genetic and chronic conditions, the initial achievements of RNA-based treatments, heightened investment in genomic research, and the elucidation of RNA interference pathways.
The small interfering RNA market is projected to experience rapid expansion over the coming years, with its value anticipated to reach $47.07 billion by 2030, reflecting a compound annual growth rate of 20%. This forecast period’s growth is driven by several factors, including a higher number of regulatory approvals for RNA-based therapies, an increased demand for personalized medicine, advances in nanoparticle delivery technologies, greater financial commitments from pharmaceutical firms, and the expanding use of siRNA in addressing infectious and rare conditions. Key trends that will shape this period encompass the wider clinical integration of RNA interference treatments, a stronger focus on targeted gene silencing methods, the evolution of sophisticated delivery platforms for siRNA, increased investment in precision therapeutic development, and a greater emphasis on scalable RNA production processes.
Download A Free Sample Report For Comprehensive Market Insights:
Small Interfering Ribonucleic Acid (RNA) Market Demand Drivers Creating New Revenue Opportunities
The growing interest in personalized medicine is expected to drive expansion within the small interfering ribonucleic acid (RNA) market moving forward. Personalized medicine represents a healthcare strategy centered on customizing treatments for individual patients by accounting for their genetic makeup, environmental influences, and lifestyle choices, all aimed at enhancing treatment outcomes and elevating the quality of care. This increasing demand for personalized medicine can be attributed to progress in genomic technologies, which allow for more accurate detection of genetic variations and support the development of tailored therapies for specific individuals. Small interfering ribonucleic acid (siRNA) contributes to advances in personalized medicine through its ability to facilitate targeted gene silencing, making it especially well-suited for addressing particular genetic disorders and diseases. By precisely blocking the disease-causing mRNA, siRNA helps reduce off-target effects, thereby boosting therapeutic effectiveness and improving results for patients. As an example, data from the Personalized Medicine Coalition (PMC), a nonprofit organization based in the United States, indicated in February 2024 that the U.S. Food and Drug Administration (FDA) authorized 26 new personalized medicines in 2023, marking a notable increase compared to the 12 approvals granted in 2022. Consequently, this rising demand for personalized medicine continues to fuel growth in the small interfering ribonucleic acid (RNA) market.
Small Interfering Ribonucleic Acid (RNA) Market Segment Analysis Highlighting Growth Areas
The small interfering ribonucleic acid (rna) market covered in this report is segmented –
1) By Type: Liposome Systemic Therapy, Nanoparticle-Based Systemic Therapy
2) By Indication: Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases
3) By End-User: Hospital, Research Institutions, Pharmaceutical And Biotechnology Companies, Academic Institutions
Subsegments:
1) By Liposome Systemic Therapy: Cationic Liposome Delivery, Neutral Liposome Delivery, Pegylated Liposome Delivery, Targeted Liposome Delivery
2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery, Polymer Nanoparticle Delivery, Gold Nanoparticle Delivery, Silica Nanoparticle Delivery
Small Interfering Ribonucleic Acid (RNA) Market Trends Driving Strategic Industry Expansion
Key players in the siRNA therapeutics sector are prioritizing the acquisition of regulatory endorsements for innovative approaches aimed at treating uncommon hereditary disorders, with the goal of delivering long-lasting benefits and decreasing how often patients need to take medication. Such official approvals represent clearances from governing bodies that authorize a drug or treatment to be safely assessed, promoted, or administered to patients. As an example, in March 2025, Alnylam Pharmaceuticals Inc., a biopharmaceutical firm headquartered in the United States, secured authorization from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran), marking the debut of a small interfering RNA-based therapy for adults and adolescents twelve years of age and older diagnosed with hemophilia A or B, whether inhibitors are present or not. This treatment works by reducing antithrombin levels, which consequently boosts thrombin production to support blood clot formation and minimize incidents of bleeding. Qfitlia is administered subcutaneously every two months, presenting a novel, non-factor therapeutic alternative for managing hemophilia.
Small Interfering Ribonucleic Acid (RNA) Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.
Access The Complete Small Interfering Ribonucleic Acid (RNA) Market Report:
Small Interfering Ribonucleic Acid (RNA) Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in the small interfering ribonucleic acid (rna) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
